OA12981A - Substituted pyrazoles as p38 kinase inhibitors. - Google Patents

Substituted pyrazoles as p38 kinase inhibitors. Download PDF

Info

Publication number
OA12981A
OA12981A OA9900252A OA9900252A OA12981A OA 12981 A OA12981 A OA 12981A OA 9900252 A OA9900252 A OA 9900252A OA 9900252 A OA9900252 A OA 9900252A OA 12981 A OA12981 A OA 12981A
Authority
OA
OAPI
Prior art keywords
pyrazol
alkyl
methyl
aryl
heterocyclyl
Prior art date
Application number
OA9900252A
Other languages
English (en)
Inventor
Ashok Anantanarayan
Michael Clare
Paul W Collins
Joyce Zuowu Crich
Rajesh Devraj
Daniel L Flynn
Lifeng Geng
Gunnar J Hanson
Francis J Koszyk
Shuyuan Liao
Richard A Partis
Shashidhar N Rao
Shaun Raj Selness
Michael S South
Michael A Stealey
Richard M Weier
Xiangdong Xu
Ish K Kanna
Yi Yu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of OA12981A publication Critical patent/OA12981A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA9900252A 1997-05-22 1999-11-22 Substituted pyrazoles as p38 kinase inhibitors. OA12981A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22

Publications (1)

Publication Number Publication Date
OA12981A true OA12981A (en) 2006-10-13

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900252A OA12981A (en) 1997-05-22 1999-11-22 Substituted pyrazoles as p38 kinase inhibitors.

Country Status (24)

Country Link
EP (1) EP1000055A1 (is)
JP (1) JP2002508754A (is)
KR (1) KR20010012854A (is)
CN (1) CN1264377A (is)
AP (1) AP1246A (is)
AU (1) AU754830C (is)
BG (1) BG64313B1 (is)
BR (1) BR9809147A (is)
CA (1) CA2291115A1 (is)
EA (1) EA003925B1 (is)
EE (1) EE9900527A (is)
GE (1) GEP20033053B (is)
HU (1) HUP0001880A3 (is)
ID (1) ID22982A (is)
IL (1) IL132991A (is)
IS (1) IS5257A (is)
NO (1) NO995695L (is)
NZ (1) NZ501112A (is)
OA (1) OA12981A (is)
PL (1) PL337020A1 (is)
SK (1) SK157899A3 (is)
TR (1) TR200000235T2 (is)
WO (1) WO1998052940A1 (is)
ZA (1) ZA984358B (is)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (is) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6649617B1 (en) 1998-10-07 2003-11-18 Smithkline Beecham Corporation Treatment for stroke management
DE69914357T2 (de) 1998-11-04 2004-11-11 Smithkline Beecham Corp. Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
CA2355075C (en) 1998-12-16 2009-12-08 Aventis Pharma Limited Heteroaryl-cyclic acetals
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
KR100711538B1 (ko) * 1998-12-25 2007-04-27 아스카 세이야쿠 가부시키가이샤 아미노피라졸 유도체
TW502019B (en) 1999-03-26 2002-09-11 Cocensys Inc Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
DE60020560T2 (de) 1999-06-03 2006-04-27 Teikoku Hormone Mfg. Co., Ltd. Substituierte pyrazol-derivate
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
BR0013551A (pt) * 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
AU7922100A (en) * 1999-10-25 2001-05-08 Basf Aktiengesellschaft Agrochemical compositions containing pyrazoles as the active agents and use of said compositions as plant protection agents with a fungicidal action
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1233950B1 (en) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
ATE281439T1 (de) 1999-11-23 2004-11-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
HK1052705B (en) 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
SK287857B6 (sk) 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
AU2002330096B2 (en) 2001-09-25 2007-11-08 Pharmacia Corporation Process for making substituted pyrazoles
RU2277534C2 (ru) * 2001-09-25 2006-06-10 Фармация Корпорейшн Способ получения замещенных пиразолов
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
TW200400960A (en) * 2002-06-05 2004-01-16 Pharmacia Corp Novel pyrazoles and their use as P38 kinase inhibitors
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004026302A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
US7622471B2 (en) 2003-02-07 2009-11-24 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives having a pyridazine and pyridine functionality
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EA012119B1 (ru) 2004-08-12 2009-08-28 Пфайзер Инк. ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US7939536B2 (en) 2004-12-28 2011-05-10 Aska Pharmaceutical Co., Ltd. Pyrimidinylisoxazole derivatives
WO2007105058A2 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
EP2036905B1 (en) 2006-06-28 2012-12-12 ASKA Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
WO2008001929A1 (en) 2006-06-28 2008-01-03 Aska Pharmaceutical Co., Ltd. Treatment agent for inflammatory bowel disease
AU2008215659B2 (en) 2007-02-16 2012-11-01 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
JP2010533147A (ja) * 2007-07-13 2010-10-21 アデックス ファルマ エス．エイ． 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体
TW200927115A (en) 2007-11-16 2009-07-01 Boehringer Ingelheim Int Aryl-and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CL2009000904A1 (es) * 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
AR071719A1 (es) 2008-05-13 2010-07-07 Boehringer Ingelheim Int Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion
PT2324008E (pt) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
CA2735204C (en) * 2008-08-25 2017-06-20 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
CN102177138A (zh) * 2008-10-23 2011-09-07 隆萨有限公司 合成取代的吡唑类的方法
MX2011005221A (es) * 2008-11-21 2011-08-03 Raqualia Pharma Inc Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b.
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
IN2012DN01693A (is) * 2009-08-26 2015-06-05 Novartis Ag
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
CN102762551A (zh) 2009-12-21 2012-10-31 拜尔农作物科学股份公司 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途
CN104958294A (zh) 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
CA2819961C (en) * 2010-12-20 2015-08-18 Pfizer Inc. Novel fused pyridine compounds as casein kinase inhibitors
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
WO2013025664A1 (en) 2011-08-17 2013-02-21 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
MX355016B (es) 2011-10-06 2018-04-02 Bayer Ip Gmbh Heterociclilpiri(mi)dinilpirazoles como fungicidas.
JP6211522B2 (ja) 2011-10-06 2017-10-11 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ヘテロシクリルピリ（ミ）ジニルピラゾール
DE102011115525A1 (de) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Zweiteilige Flasche mit einem darin angeordneten Trockenmittel
RU2622015C2 (ru) 2011-11-11 2017-06-08 Новартис Аг Способ лечения пролиферативного заболевания
SI2782557T1 (sl) 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
HK1224172A1 (zh) 2013-03-15 2017-08-18 加州生物医学研究所 用於诱导软骨形成的化合物和方法
US9573904B2 (en) * 2013-12-12 2017-02-21 Sumitomo Chemical Company, Limited Aromatic compound and use thereof
CN104829536B (zh) * 2015-05-04 2017-12-29 陕西科技大学 一种具抗肿瘤活性的苯基吡唑羧酸类化合物及其合成方法
JP6746614B2 (ja) * 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
CN112480079B (zh) * 2017-11-08 2022-03-11 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020124397A1 (en) 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂
EP3978487A1 (en) * 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
JP2024503280A (ja) * 2020-12-29 2024-01-25 レボリューション メディシンズ インコーポレイテッド Ｓｏｓ１阻害剤及びその使用
WO2025231152A1 (en) * 2024-04-30 2025-11-06 The Cleveland Clinic Foundation Compounds and methods for restoring beta-adrenergic receptor function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2753659B2 (ja) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体

Also Published As

Publication number Publication date
AP1246A (en) 2004-02-07
BG64313B1 (bg) 2004-09-30
JP2002508754A (ja) 2002-03-19
SK157899A3 (en) 2000-08-14
NO995695D0 (no) 1999-11-19
IS5257A (is) 1999-11-19
CN1264377A (zh) 2000-08-23
NO995695L (no) 2000-01-21
IL132991A0 (en) 2001-03-19
ID22982A (id) 1999-12-23
EA199900953A1 (ru) 2000-10-30
CA2291115A1 (en) 1998-11-26
AU754830B2 (en) 2002-11-28
KR20010012854A (ko) 2001-02-26
ZA984358B (en) 1999-05-24
EP1000055A1 (en) 2000-05-17
EA003925B1 (ru) 2003-10-30
EE9900527A (et) 2000-06-15
HUP0001880A2 (en) 2001-03-28
AP9901715A0 (en) 1999-12-31
BG103964A (en) 2000-08-31
NZ501112A (en) 2002-10-25
GEP20033053B (en) 2003-08-25
IL132991A (en) 2005-11-20
PL337020A1 (en) 2000-07-31
WO1998052940A1 (en) 1998-11-26
AU7588398A (en) 1998-12-11
HUP0001880A3 (en) 2002-03-28
TR200000235T2 (tr) 2000-05-22
AU754830C (en) 2004-02-12
BR9809147A (pt) 2000-08-01

Similar Documents

Publication Publication Date Title
OA12981A (en) Substituted pyrazoles as p38 kinase inhibitors.
US6514977B1 (en) Substituted pyrazoles as p38 kinase inhibitors
US7071198B1 (en) Substituted pyrazoles as p38 kinase inhibitors
US20020086869A1 (en) 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors
WO2011027249A2 (en) Benzimidazole derivatives
RS60099B1 (sr) Jedinjenja i kompozicije sa nokdaun efektom ili aktivnošću inhibicije hranjenja krvlju kod štetnih insekata
EP1960382A1 (en) Heterocyclic compounds as tyrosine kinase modulators
JP2013256532A (ja) キナーゼインヒビターとして有用なアミノピリミジン
JP2018509377A (ja) 生体アミン輸送モジュレータとしてのヘテロ環式化合物
CZ411899A3 (cs) Substituované pyrazoly jako inhibitory p38 kinázy, způsob jejich přípravy a farmaceutické kompozice
HK1125107A (en) Aminopyrimidines useful as kinase inhibitors